Alluvi, known as BI 4744, offers a promising breakthrough in obesity therapy. This dual stimulator targeting both GLP-1 and GIP receptors demonstrates impressive results in patient assessments, possibly outperforming https://alluvi-research.co.uk/product/tirzepatide-40mg-rd-only-alluvi/